Cardillo M R, Yap E
Dept. of Experimental Medicine and Pathology, University La Sapienza, Rome, Italy.
J Exp Clin Cancer Res. 1997 Sep;16(3):281-8.
Transforming growth factor-beta proteins are key regulators of cellular growth and differentiation. To understand the role of TGF-beta in colonic tumour progression, 47 paraffin embedded samples from colonic tumours (13 adenomas, and 34 adenocarcinomas) were studied. Gene mutations in the region coding for the active protein were studied by PCR SSCP analysis of exons 5, 6, and 7. TGF-beta1 mRNA expression and localization were studied by NISH using cDNA probes generated by RT-PCR. Protein distribution was investigated by immunohistochemistry using antibodies against both intracellular and extracellular forms. Three mutations were found: one in exon 5 (Dukes C) and two in exon 7 (Dukes C and A). TGF-beta1 mRNA was observed in 9 (69%) of 13 adenomas and in 30 (88%) of 34 adenocarcinomas. Levels of TGF-beta1 mRNA and proteins were higher in colorectal carcinomas than in colorectal adenomas. Tubular adenomas associated with dysplasia showed greater expression of TGF-beta1 than adenomas without dysplasia and than non-neoplastic colonic mucosa. In dysplasia and cancer, epithelial neoplastic cells and stromal cells were positive for TGF-beta1. In normal tissue endothelial cells and granulocytes sporadically showed immunoreactivity for TGF-beta1, whereas epithelial cells were all negative. The three mutations in TGF-beta1 exons 5, 6 and 7 found in colorectal adenocarcinomas suggest that TGF-beta1 mutation may play a role in colorectal carcinogenesis and that the presence of the mutant form contributes to the transformed state. Our two other findings, the loss of staining gradient in normal colonic mucosa and the higher levels of TGF-beta1 mRNA and proteins in colorectal carcinomas than in colorectal adenomas, indicate that the de-regulation of TGF-beta1 expression may occur as an early event in colorectal carcinogenesis. Although TGF-beta1 expression is generally a reflection of cellular differentiation, tumour grade is not associated with TGF-beta1 mRNA expression. Beside being present in the epithelial cells of the colonic tumours, TGF-beta1 mRNA also occurred in the stroma: its localization in the macrophages adjacent to tumour strongly suggests that TGF-beta1 could be secreted by macrophages. This hypothesis should lead to new therapeutic strategies for colorectal carcinoma.
转化生长因子-β蛋白是细胞生长和分化的关键调节因子。为了解转化生长因子-β在结肠肿瘤进展中的作用,我们研究了47例来自结肠肿瘤的石蜡包埋样本(13例腺瘤和34例腺癌)。通过对第5、6和7外显子进行PCR-SSCP分析,研究了活性蛋白编码区域的基因突变。使用通过RT-PCR产生的cDNA探针,通过核酸原位杂交研究了转化生长因子-β1 mRNA的表达和定位。使用针对细胞内和细胞外形式的抗体,通过免疫组织化学研究了蛋白分布。发现了三个突变:一个在第5外显子(杜克C期),两个在第7外显子(杜克C期和A期)。在13例腺瘤中有9例(69%)观察到转化生长因子-β1 mRNA,在34例腺癌中有30例(88%)观察到。结直肠癌中转化生长因子-β1 mRNA和蛋白水平高于结直肠腺瘤。与发育异常相关的管状腺瘤比无发育异常的腺瘤和非肿瘤性结肠黏膜显示出更高的转化生长因子-β1表达。在发育异常和癌症中,上皮性肿瘤细胞和基质细胞转化生长因子-β1呈阳性。在正常组织中,内皮细胞和粒细胞偶尔显示出转化生长因子-β1免疫反应性,而上皮细胞均为阴性。在结直肠腺癌中发现转化生长因子-β1第5、6和7外显子的三个突变表明,转化生长因子-β1突变可能在结直肠癌发生中起作用,并且突变形式的存在有助于肿瘤转化状态。我们的另外两个发现,正常结肠黏膜中染色梯度的丧失以及结直肠癌中转化生长因子-β1 mRNA和蛋白水平高于结直肠腺瘤,表明转化生长因子-β1表达失调可能是结直肠癌发生的早期事件。虽然转化生长因子-β1表达通常反映细胞分化,但肿瘤分级与转化生长因子-β1 mRNA表达无关。除了存在于结肠肿瘤的上皮细胞中,转化生长因子-β1 mRNA也出现在基质中:其在肿瘤邻近巨噬细胞中的定位强烈表明转化生长因子-β1可能由巨噬细胞分泌。这一假说应该会带来结直肠癌的新治疗策略。